Arena Healthcare

News

Argenica Therapeutics greenlit to launch Phase II trials into stroke treatment

The Australian company developing ARG-007 to treat death of brain cells following a stroke has received the nod to begin Phase II trials.

Joshua Silverwood
close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close